Compound DAO is voting on whether to renew Gauntlet’s $2.3M risk contract for another year.

Alphagrowth wrote a case against:

– Fixed $2.3M annual fee with little downside protection

– Weak ROI from incentive programs

– Unclear parameter change rationale

– Conflict of interest via Morpho grants

Maybe agreement should be performance based ?

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。